Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Wed, 22.11.2023       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin/Würzburg, 22 November 2023. Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today has announced that a first patient has been treated in a dose-finding clinical phase I/II study with Yttrium (90Y) anditixafortide (PentixaTher) at the University  [ … ]
Technical analysis
To the publication
Tue, 21.11.2023       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, November 21, 2023. Dr. Hakim Bouterfa, Executive Board member of Eckert & Ziegler AG and responsible for clinical development, will leave the Executive Board of Eckert & Ziegler AG at the end of the year and in future will concentrate exclusively on his tasks as Executive Board member of the Eckert & Ziegler subsidiary Pentixaph [ … ]
Technical analysis
To the publication
Tue, 14.11.2023       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, 14.11.2023. Eckert & Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma). Eckert & Ziegler will benefit from the cooperation between the two companies above all at its prod [ … ]
Technical analysis
To the publication
Tue, 14.11.2023       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, 14 November 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) achieved sales of € 183.9 million in the first nine months of 2023 (previous year: € 165.8 million) and consolidated net income of € 20.3 million (previous year: € 21.7 million). Adjusted for currency losses of € 3.3 million, the nine-month resu [ … ]
Technical analysis
To the publication
Mon, 23.10.2023       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, Germany and Shanghai, China – 23 October 2023 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a. 177Lu). Eckert & Ziegler will serve as the supplier for Ablaze’s clinical trial and research activities utilizing Lutetium-1 [ … ]
Technical analysis
To the publication
Fri, 20.10.2023       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, 20 October 2023. Berlin, xx.10.2023. The Executive Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) resolved at its meeting today, with the approval of the Supervisory Board, the strategy and investment priorities for the coming years. In this context the Supervisory Board of Eckert & Ziegler AG  has given its approval to the  [ … ]
Technical analysis
To the publication
Fri, 20.10.2023       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, 20 October 2023. The Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today has given its approval to the Executive Board to examine and prepare a split-off of up to 100 percent of the shares in the Pentixapharm AG (PTX). In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the  [ … ]
Technical analysis
To the publication
Tue, 17.10.2023       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Q3 2023: sales of 65.9 million EUR (previous year: 57.2 million EUR) profit of 9.4 million EUR (previous year: 7.9 million EUR) First 9 months of 2023: sales of 183.9 million EUR (previous year: 164.0 million EUR) profit of 20.3 million EUR (previous year: 23.3 million EUR) Forecast 2023: sales of just under 230 million EUR (confirmed) profit [ … ]
Technical analysis
To the publication
Tue, 10.10.2023       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, Germany and BOCA RATON, FL, USA – 10 October 2023 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and PharmaLogic Holdings Corp. (“PharmaLogic”) have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225 (Ac-225). Under the terms of the agreement, PharmaLogic will have access to Eckert & Ziegler's h [ … ]
Technical analysis
To the publication
Thu, 28.09.2023       Eckert & Ziegler Strahlen- und Medizintechnik AG
DE0005659700

Berlin, September 28, 2023. Eckert & Ziegler AG has been awarded the Pankow 2023 Training Prize for outstanding training quality. The award was presented yesterday at a celebration event by Berlin-Pankow District Mayor Dr. Cordelia Koch. The jury justified the award with the great commitment to professional training and the special training co [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 07.07.2024, Calendar Week 27, 189th day of the year, 177 days remaining until EoY.